Overview of SPA-S-843 in vitro activity against filamentous fungi

Chemotherapy

Volumn 46, Issue 1, 2000, Pages 28-35

  Rimaroli, Claudio ^a,b   Bruzzese, Tiberio ^a  

^a Societa Prodotti Antibiotici SpA ^*  (Italy)

^b c/o Societa Prodotti Antibiotici SpA ^*  (Italy)

Author keywords

Antifungal activity, in vitro; Minimum fungicidal concentrations; Minimum inhibitory concentrations; Polyenes; SPA S 843

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; SPA S 843; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; FUNGICIDAL ACTIVITY; MICROSPORUM; MINIMUM INHIBITORY CONCENTRATION; MUCOR; NONHUMAN; PAECILOMYCES; PENICILLIUM; PRIORITY JOURNAL; RHIZOPUS; SPOROTHRIX SCHENCKII; TRICHOPHYTON;

EID: 0033987172     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007253     Document Type: Article

References (27)

1. Anaisse EJ, Bodey GP, Rinaldi MG: Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989;8: 323-330.
2. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JE, Tolson J, Henderson T, Marone WJ: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-89. National Nosocomial Infections Surveillance System, Am J Med 1991:91(suppl 3B):86-89.
3. Hadfield TL, Smiths MB, Winn RE, Rinaldi MG, Guerra C: Mycoses caused by Candida Insitaniae. Rev Infect Dis 1987;9:1006-1012.
4. Harvey RL, Myers JP: Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987;147:2117-2120.
5. Komshian SV, Uwaydak AK, Sobel JD, Crane LR: Fungemia caused by Candida species and Candida glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of influencing outcome. Rev Infect Dis 1989;145:45-56.
6. Pfaller MA: Infection control: Opportunistic fungal infection - the increasing importance of Candida species. Infect Control Hosp Epidemiol 1989;9:408-416.
7. Pfaller MA, Wenzel R: Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11:287:-291.
8. Weems JJ Jr: Candida parapsilosis: Emerging hospital blood stream pathogens. Clin Infect Dis 1992;14: 756-766.
9. Wenzel RP, Pfaller MA: Candida species: Epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Infect Control Hosp Epidemiol 1991;12: 523-524.
10. Sabra R, Branch RA: Amphotericin B nephrotoxicity. Drug Saf 1990;5: 94-108.
11. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR: Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms in individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37:2449-2453.
12. Hitchcock CA, Pyc GW, Troke PF, Warnock DW: Fluconazole resistance in Candida glabrata. Antimibrob Agents Chemother 1993;37: 1962-1965.
13. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, Pfaller M: Development of resistance to fluconazole among isolates of Candida albicans obtained during treatment of oropharyngeal candidiasis in AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-242.
14. Willocks L, Leen CLS, Brettle RP, Urquhart D, Russel TB, Milne LJR: Fluconazole resistance in AIDS patients. J Antimicrob Chemother 1991;28:937-939.
15. Bruzzese T, Binda I, Ghielmetti G, Notarianni AF: Partricin, an antifungal and antiprotozoal polyene antibiotic. Farmaco [Sci] 1974;29: 331-334.
16. Bruzzese T, Cambieri M, Recusani F: Synthesis and biological properties of alkyl esters of polyene antibiotics. J Pharm Sci 1975;64:462-463.
17. Bruzzese T, Binda I, Di Nardo A, Ghielmetti G, Riva M: Partricin methyl ester, a semisynthetic polyene antibiotic. Experientia 1972; 28:1515.
18. Golik J, Zielinski J, Borowski E: The structure of mepartricin A and mepartricin B. J Antibiotics 1980;33: 904-907.
19. Tweit RC, Pandey RC. Rinehart K Jr: Characterization of the antifungal and antiprotozoal antibiotic partricin and structural studies on partricin A and B. J Antibiotics 1982; 35:997-1012.
20. Bruzzese T, Rimaroli C, Bonabello A, Ferrari E, Signorini M: Amide derivatives of partricin A with potent antifungal activity. Eur J Med Chem 1996;31:965-972.
21. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeast. Approved Standard M27-A. Wayne, National Committee for Clinical Laboratory Standards, 1997.
22. Espinel-Ingroff A, Bartlett M, Bowden R, Chin NX, Cooper C Jr, Fothergill A, McGinnis MR, Menezes P, Messer SA, Nelson PW, Odds FC, Pasarell L, Peter J, Pfaller MA, Rex JH, Rinaldi MG, Shankland GS, Walsh TJ, Weitzman I: Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35:139-143.
23. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, Fothergill A, Paetznick V, Peter J, Rinaldi M, Walsh T: Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39:314-319.
24. Rimaroli C, Bruzzese T: In vitro activity of a new polyene, SPA-S-843, against yeasts. Antimicrob Agents Chemother 1998;43:3012-3013.
25. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE: in vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 1995;39:295-300.
26. Shadomy S, Pfaller MA: Laboratory studies with antifungal agents: Susceptibility tests and quantitation in body fluids; in Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ (eds): Manual of Clinical Microbiology, ed 5. Washington. American Society for Microbiology, 1991, pp 1173-1183.
27. Bonabello A, Bruzzese T: Antifungal activity of SPA-S-843, in comparison with amphotericin B and fluconazole, on murine experimental infections (abstract P-89). Abstracts Trends Invas Fungal Infect 4, Barcelona, 1997, p 137.